Geode Capital Management
NYMX

Geode Capital Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Geode Capital Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,678
Closed -$9.63K – 4886
2023
Q2 		$9.63K Hold
50,678
– – ﹤0.01% 4718
2023
Q1 		$17.2K Hold
50,678
– – ﹤0.01% 4720
2022
Q4 		$15K Hold
50,678
– – ﹤0.01% 4805
2022
Q3 		$21K Hold
50,678
– – ﹤0.01% 4911
2022
Q2 		$22K Hold
50,678
– – ﹤0.01% 4912
2022
Q1 		$63K Hold
50,678
– – ﹤0.01% 4766
2021
Q4 		$65K Sell
50,678
-53
-0.1% -$85 ﹤0.01% 4816
2021
Q3 		$104K Buy
50,731
+9,086
+22% +$16.1K ﹤0.01% 4663
2021
Q2 		$65K Sell
41,645
-261,410
-86% -$485K ﹤0.01% 4626
2021
Q1 		$672K Buy
303,055
+3,262
+1% +$8.6K ﹤0.01% 3707
2020
Q4 		$743K Buy
299,793
+2,557
+0.9% +$5.65K ﹤0.01% 3460
2020
Q3 		$731K Buy
297,236
+12,406
+4% +$36.1K ﹤0.01% 3311
2020
Q2 		$1.01M Buy
284,830
+243,238
+585% +$769K ﹤0.01% 3132
2020
Q1 		$97K Buy
41,592
+15,420
+59% +$43.3K ﹤0.01% 3777
2019
Q4 		$57K Hold
26,172
– – ﹤0.01% 4072
2019
Q3 		$48K Sell
26,172
-833
-3% -$1.46K ﹤0.01% 4068
2019
Q2 		$39K Sell
27,005
-122,349
-82% -$214K ﹤0.01% 4106
2019
Q1 		$294K Buy
149,354
+15,333
+11% +$32.5K ﹤0.01% 3620
2018
Q4 		$175K Buy
134,021
+13,103
+11% +$24K ﹤0.01% 3712
2018
Q3 		$297K Buy
120,918
+11,132
+10% +$32.9K ﹤0.01% 3628
2018
Q2 		$368K Buy
109,786
+19,284
+21% +$74.1K ﹤0.01% 3530
2018
Q1 		$382K Buy
90,502
+1,306
+1% +$4.53K ﹤0.01% 3487
2017
Q4 		$294K Buy
89,196
+8,021
+10% +$29.3K ﹤0.01% 3545
2017
Q3 		$310K Buy
81,175
+7,068
+10% +$26.8K ﹤0.01% 3519
2017
Q2 		$326K Buy
74,107
+52,826
+248% +$217K ﹤0.01% 3511
2017
Q1 		$77K Buy
21,281
+468
+2% +$1.54K ﹤0.01% 3875
2016
Q4 		$55K Buy
20,813
+6,504
+45% +$20.2K ﹤0.01% 3897
2016
Q3 		$46K Buy
14,309
+78
+0.5% +$255 ﹤0.01% 3923
2016
Q2 		$47K Hold
14,231
– – ﹤0.01% 3936
2016
Q1 		$34 Sell
14,231
-78
-0.5% -$184 ﹤0.01% 4015
2015
Q4 		$46K Buy
+14,309
New +$48K ﹤0.01% 4017

Other funds holding NYMX

DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
CAM
Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return
ODIJL
One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Geode Capital Management's NYMX Position: Q3 2023 in Review

Geode Capital Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 50,678 shares — an estimated $9.63K sold.

Geode Capital Management first reported a position in NYMX in Q4 2015 and held it in 31 quarters. The position peaked at $1.01M in Q2 2020. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

  • Geode Capital Management reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
  • Geode Capital Management sold 50,678 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $9.63K.
  • Geode Capital Management first reported a position in Nymox Pharmaceutical Corp in Q4 2015 and held it in 31 quarters.
  • Geode Capital Management's Nymox Pharmaceutical Corp position peaked at $1.01M in Q2 2020.
  • 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.